Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

ACCESSAFRICA2

Financiado

Strengthening Clinical Trial Regulatory and Ethical review Oversight in East Afr...

There is an increase in the number of drug development clinical trials conducted in Sub-Saharan Africa (SSA), including vaccine development studies for poverty-related diseases (PRDs) underway in SSA. These increases have not been... ver más

30/06/2026

Innovasjon Norge

600K€

Presupuesto del proyecto: 600K€

Líder del proyecto

Innovasjon Norge No se ha especificado una descripción o un objeto social para esta compañía.

Ver 5 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-04-28

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

HORIZON-JU-GH-EDCTP3-2022-CALL1-01-05: Strengthening regulatory capacity for supporting conduct of clinical trials

Innovación

Cerrada hace 2 años

0% 100% 100%

5 Participantes

Innovasjon Norge

208.60K€ | Lider

JIMMA UNIVERSITY

UGANDA NATIONAL HEALTH RESEA...

Proyectos interesantes

SEARCH II Strengthening Regulatory Capacities for Clinical Trials Over... 600K€ Cerrado

EU2P European programme in Pharmacovigilance and Pharmacoepidemio... 8M€ Cerrado

SCALE-IT SCALING UP CAPACITY TO SUPPORT CONDUCT OF CLINICAL TRIALS IN... 600K€ Cerrado

CAPACITY 2023 CONSORTIUM FOR DEVELOPING REGULATORY CAPACITY FOR CLINICAL T... 999K€ Cerrado

WEB-RADR Recognising Adverse Drug Reactions 6M€ Cerrado

SAFESCIMET European Modular Education and Training Programme in Safety... 6M€ Cerrado

Últimas noticias

29-11-2024: IDAE En las últimas 48 horas el Organismo IDAE ha otorgado 4 concesiones

29-11-2024: ECE En las últimas 48 horas el Organismo ECE ha otorgado 2 concesiones

29-11-2024: CMVAMADRID En las últimas 48 horas el Organismo CMVAMADRID ha otorgado 37 concesiones

Duración del proyecto: 38 meses Fecha Inicio: 2023-04-28
Fecha Fin: 2026-06-30

Líder del proyecto

Innovasjon Norge

Presupuesto del proyecto 600K€

Descripción del proyecto There is an increase in the number of drug development clinical trials conducted in Sub-Saharan Africa (SSA), including vaccine development studies for poverty-related diseases (PRDs) underway in SSA. These increases have not been matched with increase in regulatory support and ethical review for such studies in SSA. Specific gaps exist in skills and knowledge in providing adequate regulatory oversight, ethical review and pharmacovigilance for such studies, efficiency of the regulatory and ethical review processes. With sequential processes of review requiring a prolonged period before approvals are granted, there is dissatisfaction with the the time interval from submission to decision, within the research community. Additionally, mechanisms for reporting adverse events to both the ethics committees and national regulators are not well developed. The Aim of AccessAfrica 2 is to improve ethical review and regulatory capacity for clinical trials in two Sub-Saharan Africa (SSA) countries, with specific focus on the review and oversight of reported adverse events during clinical trials, improve efficiencies of the NECs and NRAs, and equip them with skills and knowledge for oversight for novel research designs. AccessAfrica 2 is a embedded in the Eastern Africa Consortium for Clinical Research (EACCR), and EDCT funded network, and is continuation of AccessAfrica project which was funded by EDCTP. We propose to address the identified gaps through the three objectives and four work packages. We will establish a consensus driven consortium with partners leveraging each others strength to achieve the objectives. We propose to incorporate the AVAREF guidelines in the regulatory and ethical review guidelines of the partners, and work with the Kenya Pharmacy and Poisons board to improve the pharmacovigilance for research capacity in the partner countries.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores